Alnylam Pharmaceuticals Aktie - Fundamentalanalyse - Dividendenrendite KGV
Alnylam Pharmaceuticals (ISIN: US02043Q1076, WKN: A0CBCK) Kursdatum: 23.04.2018 Kurs: 95,860 USD| Beschreibung | Daten |
|---|---|
| Symbol | ALNY |
| Marktkapitalisierung | 9.425.913.856,00 USD |
| Land | Vereinigte Staaten von Amerika |
| Indizes | NASDAQ Comp. |
| Sektor | Pharma |
| Rohdaten nach | US GAAP in Millionen USD |
| Aktiensplits | |
| Internet | www.alnylam.com |
| Letztes Bilanz Update | 15.02.2018 |
Fundamentaldaten
| Fundamental Verhältnisse errechnet am: 23.04.2018 | |||||||
|---|---|---|---|---|---|---|---|
| KFCV | KCV | DIV Rendite | GKR | EKQ | KGV | KUV | KBV |
| -19,36 | -24,62 | 0,00% | -26,72 | 88,55 | -17,69 | 104,84 | 5,34 |
Firmenbeschreibung
12.
QUARTERLY FINANCIAL
DATA (UNAUDITED)
The following information
has been derived from unaudited consolidated financial statements
that, in the opinion of management, include all recurring
adjustments necessary for a fair statement of such
information.
Three Months
Ended
March 31,
2015
June 30,
2015
September 30,
2015
December 31,
2015
(In thousands, except
per share data)
Revenues
$
18,537
$
8,685
$
6,324
$
7,551
Operating
expenses
70,759
81,629
84,654
100,063
Net loss
$
(50,777
)
$
(71,783
)
$
(76,792
)
$
(90,721
)
Net loss per common share
— basic and diluted
$
(0.62
)
$
(0.85
)
$
(0.91
)
$
(1.07
)
Weighted-average common
shares — basic and diluted
82,074
84,353
84,633
84,871
Three Months
Ended
March 31,
2014
June 30,
2014
September 30,
2014
December 31,
2014
(In thousands, except
per share data)
Revenues
$
8,275
$
7,295
$
10,972
$
24,019
Operating
expenses
277,339
52,300
56,171
69,731
Net loss
$
(250,943
)
$
(44,074
)
$
(43,989
)
$
(21,389
)
Net loss per common share
— basic and diluted
$
(3.70
)
$
(0.58
)
$
(0.58
)
$
(0.28
)
Weighted-average common
shares — basic and diluted
67,786
75,835
76,408
76,957
Operating expenses for
the three months ended March 31, 2014 include a $224.7 million
charge to in-process research and development expense in connection
with the purchase of the Sirna RNAi assets from Merck. During the
three months ended June 30, 2014, we recorded a credit of $3.9
million to in-process research and development expense, resulting
in $220.8 million in-process research and development expense
recorded for the year ended December 31, 2014 as a result of
this asset acquisition. See Note 3, “Significant
Agreements,” for further information.